Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.

Breslow thickness COVID-19 age diagnostic delay gender lockdown melanoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
10 May 2022
Historique:
received: 05 04 2022
revised: 29 04 2022
accepted: 06 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

At the early stages of the COVID-19 outbreak in 2020, Switzerland was among the countries with the highest number of SARS-CoV2-infections per capita in the world. Lockdowns had a remarkable impact on primary care access and resulted in postponed cancer screenings. The aim of this study was to investigate the effects of the COVID-19 lockdown on the diagnosis of melanomas and stage of melanomas at diagnosis. In this retrospective, exploratory cohort study, 1240 patients with a new diagnosis of melanoma were analyzed at five tertiary care hospitals in German-speaking Switzerland over a period of two years and three months. We compared the pre-lockdown (01/FEB/19-15/MAR/20, n = 655) with the lockdown (16/MAR/20-22/JUN/20, n = 148) and post-lockdown period (23/JUN/20-30/APR/21, n = 437) by evaluating patients' demographics and prognostic features using Breslow thickness, ulceration, subtype, and stages. We observed a short-term, two-week rise in melanoma diagnoses after the major lift of social lockdown restrictions. The difference of mean Breslow thicknesses was significantly greater in older females during the lockdown compared to the pre-lockdown (1.9 ± 1.3 mm,

Identifiants

pubmed: 35625961
pii: cancers14102360
doi: 10.3390/cancers14102360
pmc: PMC9139530
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

ESMO Open. 2021 Aug;6(4):100197
pubmed: 34474811
Cochrane Database Syst Rev. 2019 Jun 03;6:CD012352
pubmed: 31157404
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Dec;61(12):1536-1543
pubmed: 30411137
Sci Prog. 2021 Apr-Jun;104(2):368504211019854
pubmed: 34061685
Clin Exp Dermatol. 2021 Jan;46(1):145-146
pubmed: 32754962
Dermatol Ther. 2020 Nov;33(6):e14074
pubmed: 32713046
Acta Derm Venereol. 2021 Aug 25;101(8):adv00525
pubmed: 34396424
Eur J Dermatol. 2022 Jul 1;31(4):521-529
pubmed: 36094385
Oncology (Williston Park). 2020 Sep 15;34(9):343
pubmed: 32965661
ESMO Open. 2020 Oct;5(5):e000970
pubmed: 33097653
Cochrane Database Syst Rev. 2018 Dec 04;12:CD013193
pubmed: 30521686
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e427-e428
pubmed: 33780557
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Clin Exp Dermatol. 2020 Oct;45(7):900
pubmed: 32502288
Ann Surg. 2006 May;243(5):693-8; discussion 698-700
pubmed: 16633005
N Engl J Med. 2021 Jan 7;384(1):72-79
pubmed: 33406334
J Am Acad Dermatol. 2021 Apr;84(4):1096-1098
pubmed: 33352269
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27285-27291
pubmed: 33060298
JCO Glob Oncol. 2020 May;6:722-729
pubmed: 32412811
J Natl Cancer Inst. 2019 Feb 1;111(2):180-188
pubmed: 29912415
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e778-e779
pubmed: 32780876
Int J Cancer. 2022 Mar 1;150(5):816-824
pubmed: 34605003
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e351-e353
pubmed: 32362041
Asia Pac J Clin Oncol. 2021 Aug;17(4):359-367
pubmed: 33567163
Minerva Med. 2020 Aug;111(4):308-314
pubmed: 32491297
World J Surg Oncol. 2021 Dec 24;19(1):350
pubmed: 34949189
Int J Dermatol. 2021 Jan;60(1):e29-e30
pubmed: 32808276
Clin Dermatol. 2021 Sep-Oct;39(5):911-919
pubmed: 34785022
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Cancers (Basel). 2020 Jul 07;12(7):
pubmed: 32645881
J Pers. 1996 Mar;64(1):1-48
pubmed: 8656311
Am J Clin Pathol. 2021 Jan 4;155(1):64-68
pubmed: 32995855
J Am Acad Dermatol. 2021 Apr;84(4):1100-1103
pubmed: 33482258
Melanoma Res. 2016 Aug;26(4):401-8
pubmed: 26990272
Dermatol Ther. 2020 Nov;33(6):e14131
pubmed: 32757248
J Am Acad Dermatol. 2021 Sep;85(3):721-723
pubmed: 34052332
Dermatol Pract Concept. 2021 Jan 29;11(1):e2021153
pubmed: 33614221
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e164-e166
pubmed: 34753221
Melanoma Res. 2017 Apr;27(2):145-151
pubmed: 27926588

Auteurs

Lisa Kostner (L)

Department of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.

Sara Elisa Cerminara (SE)

Department of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.

Gustavo Santo Pedro Pamplona (GSP)

Department of Ophthalmology, University of Lausanne, 1004 Lausanne, Switzerland.
Department of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland.

Julia-Tatjana Maul (JT)

Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.

Reinhard Dummer (R)

Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.

Egle Ramelyte (E)

Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.

Johanna Mangana (J)

Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.

Nikolaus Benjamin Wagner (NB)

Department of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.

Antonio Cozzio (A)

Department of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.

Saskia Kreiter (S)

Department of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.

Angelika Kogler (A)

Department of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.

Markus Streit (M)

Department of Dermatology, Cantonal Hospital of Aarau, 5001 Aarau, Switzerland.

Anja Wysocki (A)

Department of Dermatology, Cantonal Hospital of Lucerne, 6000 Lucerne, Switzerland.

Alfred Zippelius (A)

Department of Theragnostics, Division of Oncology, University Hospital Basel, 4031 Basel, Switzerland.
Laboratory of Cancer Immunology and Immunotherapy, Department of Biomedicine, University of Basel, University Hospital of Basel, 4031 Basel, Switzerland.

Heinz Läubli (H)

Department of Theragnostics, Division of Oncology, University Hospital Basel, 4031 Basel, Switzerland.
Laboratory of Cancer Immunology and Immunotherapy, Department of Biomedicine, University of Basel, University Hospital of Basel, 4031 Basel, Switzerland.

Alexander Andreas Navarini (AA)

Department of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.

Lara Valeska Maul (LV)

Department of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.

Classifications MeSH